Section one: Contracting authority/entity
one.1) Name and addresses
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency
10 South Colonnade
London
E14 4PU
Contact
Major Programmes, UKHSA
majorprogrammespin@ukhsa.gov.uk
Country
United Kingdom
Region code
UKI42 - Tower Hamlets
Internet address(es)
Main address
https://www.gov.uk/government/organisations/uk-health-security-agency
Buyer's address
https://www.gov.uk/government/organisations/uk-health-security-agency
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Centralised Adult Flu Procurement
two.1.2) Main CPV code
- 33651600 - Vaccines
two.1.3) Type of contract
Supplies
two.1.4) Short description
Following the publication of the NHS Vaccination Strategy (2023), NHSE, UKHSA and DHSC are exploring whether centralising the procurement and/or supply of adult flu vaccine could deliver a more efficient and effective outcome and provide improvements on the current models.
Section six. Complementary information
six.6) Original notice reference
Notice number: 2024/S 000-034816
Section seven. Changes
seven.1.2) Text to be corrected in the original notice
Section number
II.2.4.1
Instead of
Text
UKHSA, as the potential Contracting Authority, are leading the pre-market engagement activity with the purpose to:• Gain a better understanding of the ‘as-is’ adult NHS flu programme from the perspective of vaccine manufacturers and wholesalers • Understand what impact centralising the procurement and/or supply of adult flu vaccine would potentially have on the market including current capability and capacity; options under consideration includeo Procuring Adult Flu Vaccines using a Centralised Framework Contracto UKHSA Procuring Adult Flu Vaccines and maintaining existing supply and distribution methodso UKHSA Procuring Adult Flu Vaccines and ingesting supply centrally for distribution o Maintaining the status quo• Explore any potential barriers, opportunities, benefits or risks there may be with a central procurement and/or supply approach.• Have an open dialogue with the market to ensure a full understanding of the future landscape.The market engagement will take the form of a questionnaire available via our e-procurement system, which you will be asked to complete and return. Once returned, you may be invited for a 1:1 meeting with the project team to discuss your answers and provide clarification. It is anticipated that these meetings will take place during November/December 2024.Who would we like to hear from?We are keen to engage with those suppliers who already have a licenced adult flu vaccine and/or have experience of the UK adult flu market, who have an adult flu vaccine in development, or who may have an adult flu vaccine in their future product development pipeline, and with medical logistics providers both wholesale and distribution.How to participate?The opportunity will be available on the Atamis eTendering system, access here: https://atamis-1928.my.site.com/s/Welcome . If you do not already have an account you can easily register for one via the same link. You will then be able to search for this opportunity and access the questionnaire and any other related documents. Please note that all correspondence must be conducted through the Atamis system. The response window will close at 5pm on Sunday 17th November 2024.
Read
Text
UKHSA, as the potential Contracting Authority, are leading the pre-market engagement activity with the purpose to:• Gain a better understanding of the ‘as-is’ adult NHS flu programme from the perspective of vaccine manufacturers and wholesalers • Understand what impact centralising the procurement and/or supply of adult flu vaccine would potentially have on the market including current capability and capacity; options under consideration includeo Procuring Adult Flu Vaccines using a Centralised Framework Contracto UKHSA Procuring Adult Flu Vaccines and maintaining existing supply and distribution methodso UKHSA Procuring Adult Flu Vaccines and ingesting supply centrally for distribution o Maintaining the status quo• Explore any potential barriers, opportunities, benefits or risks there may be with a central procurement and/or supply approach.• Have an open dialogue with the market to ensure a full understanding of the future landscape.The market engagement will take the form of a questionnaire available via our e-procurement system, which you will be asked to complete and return. Once returned, you may be invited for a 1:1 meeting with the project team to discuss your answers and provide clarification. It is anticipated that these meetings will take place during November/December 2024.Who would we like to hear from?We are keen to engage with those suppliers who already have a licenced adult flu vaccine and/or have experience of the UK adult flu market, who have an adult flu vaccine in development, or who may have an adult flu vaccine in their future product development pipeline, and with medical logistics providers both wholesale and distribution.How to participate?The opportunity will be available on the Atamis eTendering system, access here: https://atamis-1928.my.site.com/s/Welcome . If you do not already have an account you can easily register for one via the same link. You will then be able to search for this opportunity and access the questionnaire and any other related documents. Please note that all correspondence must be conducted through the Atamis system. The response window will close at 5pm on Friday 29th November 2024.